Phase 3 trials for DAXI in glabellar line treatment is complete and U.S. regulatory approval is anticipated in 2020. The company is also evaluating the use of DAXI in forehead lines and crow’s feet, as well as for therapeutic use in cervical dystonia, adult upper limb spasticity and plantar fasciitis. There are also plans to study DAXI for migraine use.
The release indicates this is an ongoing collaboration between the two companies and a right of first negotiation for access to TEOXANE’s novel cosmeceutical line, which also incorporates RHA technology.
“This is a transformational deal for Revance, giving us access to the fast-growing, billion-dollar U.S. dermal filler market, with a line of highly differentiated fillers that are complementary to our first and only, long-lasting neuromodulator,” says Mark Foley, president and chief executive Officer of Revance. “This deal provides commercial synergies, organizational leverage and fast-tracks the build-out of our sales organization. It also creates a broad foundation from which to launch DAXI upon anticipated approval later this year.”
Revance is targeting the second quarter of 2020 to introduce the line of TEOXANE RHA fillers in the U.S., according to the release.